Back to Results

Clinuvel Pharmaceuticals Ltd ADR (CUVL)

Clinuvel Pharmaceuticals Ltd ADR is a depositary receipt representing common stock of Clinuvel Pharmaceuticals Limited, a biopharmaceutical company listed on OTC Markets. The underlying company develops and commercializes treatments for patients with genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and other international markets. Its lead product candidate is SCENESSE, a systemic photoprotective drug for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP). The company also advances a pipeline that includes CUV9900, PR


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-CUVL
$9.93
52.6% Upside
Bargain
—
—
—
Great
—
—
—
0.4%
August 28, 2026
14.5x
1.9x
4.9x
332.1 M
158.7 M
0.1%
87.0%
23.8
7.7%
123.2%
Valuation • Fair Value

Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) Fair Value by Valuation Model

Compare the primary fair value estimate for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$9.93

Estimated upside of 52.6% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$11.46

Discounted cash flow valuation reference.

Ben Graham Formula Value

$5.05

Classic Ben Graham valuation formula reference.

DDM Fair Value

$10.44

Dividend discount model valuation reference.

EPV Fair Value

$10.16

Earnings power value estimate.

Comps Fair Value

$8.27

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

64.257 M

Current operating scale indicator.

Revenue Forecast

68.092 M

Forward revenue estimate.

EBITDA

29.144 M

Current operating profitability reference.

EBITDA Forecast

29.202 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.67

No elevated caution signal from this screen.

Altman Z-Score

23.8

Relatively strong balance-sheet zone.

FCF / Net Income

123.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 28, 2026

Days to Earnings

23

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.4%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

7.7%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) Stock Forecast & Technical Outlook

Review Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) Stock FAQ

Quick answers about Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$9.93
Estimated upside 52.6%
Valuation Rating
Undervalued
Estimated upside of 52.6%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Great
Current financial-health read

The current fair value estimate for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is $9.93. This implies an estimated upside of 52.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 52.6% versus the current market price.

An analyst price target for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is not currently available in the latest available data.

The current financial health read for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is August 28, 2026.

Based on the current data, dividend yield is 0.4%.

The current P/E ratio listed for Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is 14.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Clinuvel Pharmaceuticals Ltd ADR is 332.1 M.

The current enterprise value listed for Clinuvel Pharmaceuticals Ltd ADR is 158.7 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Clinuvel Pharmaceuticals Ltd ADR is NASDAQ-CUVL, and the stock is listed on NASDAQ.

Clinuvel Pharmaceuticals Ltd ADR (NASDAQ-CUVL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Clinuvel Pharmaceuticals Ltd ADR is 0.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Clinuvel Pharmaceuticals Ltd ADR is 87.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Incyte Corporation (INCY) Incyte Corporation (INCY)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Moderna Inc (MRNA) Moderna Inc (MRNA)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Insmed Inc (INSM) Insmed Inc (INSM)
Genmab AS (GMAB) Genmab AS (GMAB)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Arrowhead Pharmaceuticals Inc (ARWR) Arrowhead Pharmaceuticals Inc (ARWR)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)